

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Tanaka et al.

Attorney Docket No. 43512-104182

Application No./Patent No./Control No.: 10/573,166

Filed/Issue Date: March 21, 2006

Entitled:

NOVEL TARGET PROTEIN OF ANTICANCER AGENT AND NOVEL ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO

Reverse Proteomics Research Institute Co., Ltd.

(Name of Assignee)

(Type of Assignee; corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____%)

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. ☐ The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____; or ☒ a true copy of the original assignment is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
☐ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or ☐ for which a copy thereof is attached.
2. From: _____ To: _____
☐ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or ☐ for which a copy thereof is attached.
3. From: _____ To: _____
☐ The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or ☐ for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

December 20, 2006

Date

Carol Larcher

Printed or Typed Name

Telephone Number

Agent for the Applicants

Title

Customer No.: 23644

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

1454

PATENT
Attorney Docket No. _____

Gardner Carton & Douglas LLP
191 N. Wacker Drive
Suite 3700
Chicago, Illinois 60606-1698

ASSIGNMENT

WHEREAS, WE, Akito TANAKA of c/o Astellas Pharma Inc., Lead Discovery Research Laboratories, Chemistry for Leads, 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585 Japan; Akira YAMAZAKI of c/o Chemistry Research Laboratories, Research Division, Dainippon Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita-shi, Osaka 564-0053 Japan; Takeshi TSUTSUMI of c/o Kashima R&D Center, Astellas Pharma Inc., 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 Japan; Tomohiro TERADA of c/o Tsukuba Research Laboratory, NIPPON SHINYAKU CO., LTD., 14-1, Sakura 3-chome, Tsukuba-shi, Ibaraki 305-0003 Japan; Masayuki HARAMURA of c/o Chugai Pharmaceutical Co., Ltd., Kamakura Research Labs, Pharmaceutical Technology Dept., 200, Kajiwara, Kamakura-shi, Kanagawa 247-8530 Japan (the "Assignors"), have invented and own a certain invention entitled:

**NOVEL TARGET PROTEIN OF ANTICANCER AGENT AND NOVEL
ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO**

for which invention we have executed an application (provisional or non-provisional) for a U.S. patent, which was filed on March 21, 2006, under U.S. Application No. 10/573,166, and

WHEREAS, REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. of 1-9-11, Kajicho, Chiyoda-ku, Tokyo 101-0044 Japan (hereinafter referred to as Assignee), is desirous of acquiring the entire domestic and foreign right, title, and interest in and under the invention described in the patent application.

NOW, THEREFORE, for good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, we assign and transfer to the Assignee and the Assignee's legal representatives, successors and assigns the full and exclusive rights in and to the invention in the U.S. and every foreign country and the entire right, title, and interest in and to the patent application and other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, National phase applications, including petty patent applications, and utility model applications) that may be filed in the United States and every foreign country on the invention, and the patents, extensions, or derivations thereof, both foreign and domestic, that may issue thereon, and we do hereby authorize and request the Commissioner of Patents to issue U.S. patents to the above-mentioned Assignee agreeably with the terms of this assignment document.


WE HEREBY AUTHORIZE the Assignee to insert in this assignment document the filing date and application number of the application if the date and number are unavailable at the time this document is executed.

UPON SAID CONSIDERATION, we convey to the Assignee the right to make application in its own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim under the Patent Cooperation Treaty, the International Convention and/or other international arrangement for any such application the date of the U.S. application (or any other application on the invention) to gain priority with respect to other applications.

In re Appln. of Tanaka et al.
Attorney Docket No.

WE DO HEREBY COVENANT and agree with the Assignee that we will not execute any writing or do any act whatsoever conflicting with the terms of this assignment document set forth herein, and that we will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, continuation, continuation-in-part, divisional, reissued, reexamined, and National phase patents of the U.S. or of any and all foreign countries on the invention, and in enforcing any rights or choses in action accruing as a result of such applications or patents, and by executing statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, we have hereunder set our hands on the dates shown below.

Date Dec. 11, 2006 
Akito TANAKA

Date Dec. 11, 2006 Witness Osamu Okitsu
Osamu OKITSU

Date Dec. 11, 2006 Witness Hirohito Kai
Hirohito KAI

Date _____
Akira YAMAZAKI

Date _____ Witness _____

Date _____ Witness _____

WE DO HEREBY COVENANT and agree with the Assignee that we will not execute any writing or do any act whatsoever conflicting with the terms of this assignment document set forth herein, and that we will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, continuation, continuation-in-part, divisional, reissued, reexamined, and National phase patents of the U.S. or of any and all foreign countries on the invention, and in enforcing any rights or choses in action accruing as a result of such applications or patents, and by executing statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representatives of all parties hereto.


IN WITNESS WHEREOF, we have hereunder set our hands on the dates shown below.

Date _____
Akito TANAKA

Date _____ Witness _____

Date _____ Witness _____

Date December 8, 2006 _____
Akira YAMAZAKI

Date December 8, 2006 Witness 
Fuminori SATO

Date December 8, 2006 Witness Kiyoshi Yamamoto
Kiyoshi YAMAMOTO

Date 12/12/2006 Takeshi Tsutsumi
Takeshi TSUTSUMI

Date 15/12/2006 Witness Yoshihiko Morishita
Yoshihiko MORISHITA

Date 15/12/2006 Witness Masao Uchida
Masao UCHIDA

Date _____
Tomohiro TERADA

Date _____ Witness _____

Date _____ Witness _____

Date _____
Masayuki HARAMURA

Date _____ Witness _____

Date _____ Witness _____

Date _____
Takeshi TSUTSUMI

Date _____ Witness _____

Date _____ Witness _____

Date December. 14. 2006. Tomohiro Terada
Tomohiro TERADA

Date December. 14. 2006 Witness Hiroki Hayase
Hiroki HAYASE

Date December. 14. 2006 Witness Tatsuya Morimoto
Tatsuya MORIMOTO

Date _____
Masayuki HARAMURA

Date _____ Witness _____

Date _____ Witness _____

Date _____
Takeshi TSUTSUMI

Date _____ Witness _____

Date _____ Witness _____

=====


Date _____
Tomohiro TERADA

Date _____ Witness _____

Date _____ Witness _____

=====

Date 12/11/2006 
Masayuki HARAMURA

Date 12/11/2006 Witness 
Masahiro AOKI

Date 12/12/2006 Witness 
Kunio KITADA